CareDx, Inc ( CDNA) Stock. Should you Buy or Sell? $ 19.19
0.49 (2.49 %)
CareDx, Inc Analysis
Updated on 10-09-2022| Symbol | CDNA |
| Price | $19.19 |
| Beta | 0.879 |
| Volume Avg. | $831.01 thousand |
| Market Cap | $1.03 B |
| 52 Week Range | $17.08 - $75.92 |
CareDx, Inc opened the day at $19.19 which is +'2.49 % on yesterday's close. CareDx, Inc has a 52 week high of $75.92 and 52 week low of $17.08, which is a difference of $58.84. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.03 B and total net profit is $296397000 which means the company is trading at 3.46 times profit to market capitalization. Theoretically, if you were to buy CareDx, Inc for $1.03 B, it would take 15 years to get your money back. CareDx, Inc are in the Diagnostics & Research space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
CareDx, Inc Stock Forecast - Is CareDx, Inc a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -14.726 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -0.220 |
Valuing CareDx, Inc
| Price Book Value Ratio | 2.304 | Price To Book Ratio | 2.304 |
| Price To Sales Ratio | 3.245 | Price Earnings Ratio | -14.726 |
How liquid is CareDx, Inc
| Current Ratio | 5.148 |
| Quick Ratio | 4.797 |
Debt
| Debt Ratio | 0.181 | Debt Equity Ratio | 0.220 |
| Long Term Debt To Capitalization | 0.035 | Total Debt To Capitalization | 0.041 |
Latest news about CareDx, Inc
Cathie Wood-led Ark Investment Management loaded up on 153,917 shares of precision medicine company CareDx Inc (NASDAQ: CDNA), via the ARK Genomic Revolution ETF (NYSE: ARKG
Which of the healthcare diagnostic services producers is now a better buy to help build your portfolio's near-term capital value? Near-term only, repetition provides long term. Find out here what the best-informed, big-$ investors now think likely to happen (good and bad) in the next 3+ months to prices of several stocks now seen attractively priced.
CareDx, Inc. (NASDAQ:CDNA ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Brandon Couillard - Jefferies Jacob Johnson - Stephens Yi Chen - H.C. Wainwright E.V.
CareDx, Inc (NASDAQ:CDNA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Ian Cooney - VP of IR Reg Seeto - CEO Ankur Dhingra - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Inc. Operator Good day, and welcome to the CareDx First Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.
CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
About CareDx, Inc
Description :
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
